QUOTE AND NEWS
Benzinga  8 hrs ago  Comment 
Analysts at Piper Jaffray upgraded The Finish Line (NASDAQ: FINL) from Neutral to Overweight. The price target for Finish Line has been raised from $28.00 to $31.00. Finish Line's shares closed at $25.74 in pre-market trading. Latest...
MarketWatch  Oct 27  Comment 
A Piper Jaffray equity analyst cut his price target on Sarepta Therapeutics Inc. Monday. The price-target cut came after the company said it will delay its new drug application for eteplirsen, a Duchenne Muscular Dystrophy treatment. Analyst...
Benzinga  Oct 16  Comment 
Analysts at Piper Jaffray upgraded Illumina (NASDAQ: ILMN) from Neutral to Overweight. The price target for Illumina has been raised from $166.00 to $192.00. Illumina shares have gained 87.08% over the past 52 weeks, while the S&P 500 index...
Benzinga  Oct 15  Comment 
Analysts at Piper Jaffray upgraded United Natural Foods (NASDAQ: UNFI) from Neutral to Overweight. The price target for United Natural Foods has been raised from $70 to $74. United Natural Foods shares have dropped 7.05% over the past 52...
Benzinga  Oct 13  Comment 
In a report published Monday, Piper Jaffray analyst Brooks E. West reiterated an Overweight rating and $79.00 price target on St. Jude Medical (NYSE: STJ). In the report, Piper Jaffray noted, “STJ shares have been pressured by FX (STJ does not...
Benzinga  Oct 13  Comment 
In a report published Monday, Piper Jaffray analyst Nicole Miller Regan downgraded the rating on Darden Restaurants, Inc. (NYSE: DRI) from Overweight to Neutral, and lowered the price target from $55.00 to $50.00. In the report, Piper Jaffray...
Benzinga  Oct 13  Comment 
In a report published Monday, Piper Jaffray analyst Jason S. Deleeuw reiterated an Overweight rating on MasterCard (NYSE: MA), but lowered the price target from $91.00 to $88.00. In the report, Piper Jaffray noted, “We believe MA's 3Q14...
Benzinga  Oct 13  Comment 
Analysts at Piper Jaffray upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Overweight. The price target for Vertex Pharmaceuticals has been raised from $87.50 to $125. Vertex Pharma shares have gained 42.08% over the past 52...
Benzinga  Oct 10  Comment 
In a report published Friday, Piper Jaffray analyst Jason S. Deleeuw initiated coverage on PennyMac Mortgage Investment Trust (NYSE: PMT) with a Neutral rating and $23.00 price target. In the report, Piper Jaffray noted, “We are initiating on...





You may also be interested in articles related to Piper Jaffray Companies (PJC):
 




You have more usfuel info than the British had colonies pre-WWII.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki